About Us
Corporate Overview
Executive Leadership
Management team
Scientific Advisory Board
Board of Directors
Clinical Advisory Board
Our Science
Pipeline
Overview
AG-73305
AG-80308
AG-86893
Disease
Overview
DME
nAMD
Other Diseases
Pterygium
Dry Eye
Clinical Trial
Investor Relations
Investors
Press Release & Publications
Allgenesis In The News
Contact Us
Press Release & Publications
Filter by
Categories
Tags
Authors
Show all
All
News
All
2015
2018
2019
2020
2021
2022
2023
All
admin
allgenesis
sky
2019-05-24
Phase 2a SURPH Trial for AG-86893
May 24th, 2019 Allgenesis In The News: A
[…]
2019-05-04
Allgenesis Presented Three Posters at ARVO 2019
May 4th, 2019 Allgenesis attended the 20
[…]
2019-02-13
Allgenesis Receives Notice of Acceptance of Australian Patent for Fusion Protein of VEGF Trap and Disintegrin
February 13th, 2019 Allgenesis Biotherap
[…]
2019-01-03
Allgenesis has been Granted Australian Patent for Multi-Tyrosine Kinase Inhibitor in Ophthalmic Suspension and its use for Treating Ocular Surface Diseases
January 3rd, 2019 Allgenesis Biotherapeu
[…]
2018-12-28
Allgenesis Biotherapeutics Inc. has been Granted U.S. Patent for Pterygium Treatment Using Multi-Tyrosine Kinase Inhibitor in Ophthalmic Suspension
December 28th, 2018 Allgenesis Biotherap
[…]
2018-11-01
Allgenesis Receives Notice of Acceptance of Australian Patent for Novel Disintegrin Variants
November 1st, 2018 Allgenesis Biotherape
[…]
Load more